It has been reported that PGC-1α activation causes significant improvements in athletic performance [24,25], prevention and treatment of muscle weakness in the elderly, obesity, and other metabolic diseases such as mitochondrial myopathies and diabetes [10,11,26]. This evidence concerns the gene PPARGC1A and obesity due to melanocortin 4 receptor deficiency.